Do some Addison's patients still make their own hormones? new study investigates.
NCT ID NCT03793114
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how many people with Addison's disease still produce small amounts of adrenal hormones like cortisol, even years after diagnosis. Researchers will test 200 adults in Norway and Sweden using blood and urine samples. The goal is to see if this leftover function affects quality of life, work ability, medication doses, or risk of adrenal crisis.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors personalize treatment for Addison's patients based on their remaining adrenal function.
- What could go wrong
- This is an observational study, not a treatment trial. It will not test any new drug or therapy, so it cannot directly improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2018
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Men and women with AAD, age 18-70 years old. This requires documented adrenal insufficiency and a positive test for 21-hydroxylase autoantibodies (biomarker for autoimmune cause) on at least one occasion. * Provided written informed consent * In case of concomitant endocrine/autoimmune diseases, the patients should be on stable adequate treatment at least the last 3 months prior to the study period. * For Norwegian AD patients: enrolled in ROAS * For Swedish AD patients: enrolled in the Swedish Addison registry Exclusion Criteria: * Antihypertensive treatment, with the exception of doxazosin, verapamil, and moxonidine. * Active malignant disease, severe heart, kidney or liver failure. * Diabetes mellitus type 1. * Pregnancy or breast feeding. * Pharmacological treatment with glucocorticoids (except their usual cortisone or hydrocortisone replacement therapy) or drugs that interfere with cortisol and catecholamine metabolism (antiepileptics, rifampicin, St. Johns wart). * Use of other glucocorticoid replacement medication than cortisone acetate or hydrocortisone. * Intake of grapefruit, grapefruit juice, or and liquorice juice the last week before or during the study period.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Primary adrenal insufficiency are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Endokrinologie in Charlottenburg
Berlin, State of Berlin, 10627, Germany
-
Haukeland University Hospital
Bergen, Bergen, 5021, Norway
-
Karolinska Institutet
Stockholm, Stockholm County, 171 77, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.